Logo image of ARGX

ARGENX SE - ADR (ARGX) Stock Fundamental Analysis

NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD

649.67  +9.77 (+1.53%)

After market: 649.67 0 (0%)

Fundamental Rating

5

ARGX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. The financial health of ARGX is average, but there are quite some concerns on its profitability. ARGX is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ARGX had positive earnings in the past year.
In the past year ARGX has reported a negative cash flow from operations.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
ARGX Yearly Net Income VS EBIT VS OCF VS FCFARGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

The Return On Assets of ARGX (13.41%) is better than 96.47% of its industry peers.
ARGX has a Return On Equity of 15.13%. This is amongst the best in the industry. ARGX outperforms 95.41% of its industry peers.
Industry RankSector Rank
ROA 13.41%
ROE 15.13%
ROIC N/A
ROA(3y)-5.24%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.94%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX Yearly ROA, ROE, ROICARGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

ARGX has a better Profit Margin (37.99%) than 98.77% of its industry peers.
ARGX's Gross Margin of 89.63% is amongst the best of the industry. ARGX outperforms 90.83% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 37.99%
GM 89.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX Yearly Profit, Operating, Gross MarginsARGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

5

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARGX has more shares outstanding
The number of shares outstanding for ARGX has been increased compared to 5 years ago.
ARGX has a worse debt/assets ratio than last year.
ARGX Yearly Shares OutstandingARGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ARGX Yearly Total Debt VS Total AssetsARGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

An Altman-Z score of 34.83 indicates that ARGX is not in any danger for bankruptcy at the moment.
The Altman-Z score of ARGX (34.83) is better than 97.88% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
ARGX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. ARGX outperforms 44.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 34.83
ROIC/WACCN/A
WACC7.57%
ARGX Yearly LT Debt VS Equity VS FCFARGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

A Current Ratio of 7.29 indicates that ARGX has no problem at all paying its short term obligations.
ARGX's Current ratio of 7.29 is fine compared to the rest of the industry. ARGX outperforms 70.19% of its industry peers.
ARGX has a Quick Ratio of 6.68. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.68, ARGX is doing good in the industry, outperforming 67.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 6.68
ARGX Yearly Current Assets VS Current LiabilitesARGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 133.66% over the past year.
ARGX shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.34%.
Measured over the past years, ARGX shows a very strong growth in Revenue. The Revenue has been growing by 94.61% on average per year.
EPS 1Y (TTM)133.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.36%
Revenue 1Y (TTM)23.34%
Revenue growth 3Y63.91%
Revenue growth 5Y94.61%
Sales Q2Q%82.18%

3.2 Future

ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 106.31% yearly.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 31.13% on average per year.
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue Next Year64.13%
Revenue Next 2Y46.91%
Revenue Next 3Y38.91%
Revenue Next 5Y31.13%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX Yearly Revenue VS EstimatesARGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ARGX Yearly EPS VS EstimatesARGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60 80 100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ARGX is valuated quite expensively with a Price/Earnings ratio of 341.93.
Based on the Price/Earnings ratio, ARGX is valued cheaply inside the industry as 91.36% of the companies are valued more expensively.
ARGX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.22.
Based on the Price/Forward Earnings ratio of 50.58, the valuation of ARGX can be described as expensive.
Based on the Price/Forward Earnings ratio, ARGX is valued cheaper than 91.36% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.86. ARGX is valued rather expensively when compared to this.
Industry RankSector Rank
PE 341.93
Fwd PE 50.58
ARGX Price Earnings VS Forward Price EarningsARGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARGX Per share dataARGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARGX's earnings are expected to grow with 155.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y242.7%
EPS Next 3Y155.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARGENX SE - ADR

NASDAQ:ARGX (5/2/2025, 8:00:01 PM)

After market: 649.67 0 (0%)

649.67

+9.77 (+1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners39.35%
Inst Owner Change0.59%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap39.67B
Analysts84.62
Price Target808.03 (24.38%)
Short Float %3.72%
Short Ratio6.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7909.56%
Min EPS beat(2)-38.07%
Max EPS beat(2)15857.2%
EPS beat(4)2
Avg EPS beat(4)3984.41%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)2003.12%
EPS beat(12)8
Avg EPS beat(12)1344.81%
EPS beat(16)12
Avg EPS beat(16)1027.8%
Revenue beat(2)2
Avg Revenue beat(2)6.37%
Min Revenue beat(2)5.75%
Max Revenue beat(2)6.99%
Revenue beat(4)3
Avg Revenue beat(4)5.41%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)9.17%
Revenue beat(8)7
Avg Revenue beat(8)8.22%
Revenue beat(12)11
Avg Revenue beat(12)28.07%
Revenue beat(16)14
Avg Revenue beat(16)44.01%
PT rev (1m)4.27%
PT rev (3m)20.58%
EPS NQ rev (1m)6.9%
EPS NQ rev (3m)37.38%
EPS NY rev (1m)0.77%
EPS NY rev (3m)14.28%
Revenue NQ rev (1m)1.51%
Revenue NQ rev (3m)8.35%
Revenue NY rev (1m)1.97%
Revenue NY rev (3m)6.1%
Valuation
Industry RankSector Rank
PE 341.93
Fwd PE 50.58
P/S 18.11
P/FCF N/A
P/OCF N/A
P/B 7.21
P/tB 7.46
EV/EBITDA N/A
EPS(TTM)1.9
EY0.29%
EPS(NY)12.84
Fwd EY1.98%
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS35.87
BVpS90.06
TBVpS87.1
PEG (NY)0.59
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.41%
ROE 15.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 37.99%
GM 89.63%
FCFM N/A
ROA(3y)-5.24%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 937.93%
Cap/Sales 3.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 6.68
Altman-Z 34.83
F-Score2
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)606.32%
Cap/Depr(5y)803.99%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.36%
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue 1Y (TTM)23.34%
Revenue growth 3Y63.91%
Revenue growth 5Y94.61%
Sales Q2Q%82.18%
Revenue Next Year64.13%
Revenue Next 2Y46.91%
Revenue Next 3Y38.91%
Revenue Next 5Y31.13%
EBIT growth 1Y96.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year959.92%
EBIT Next 3Y190.57%
EBIT Next 5Y115.14%
FCF growth 1Y67.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.24%
OCF growth 3YN/A
OCF growth 5YN/A